

H K E K
K
K

C L

K E K
K

H K L
K K K

K K



上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(K K K P K C)

(Stock Code: 02196)

2014 FIRST QUARTERLY REPORT

f 1 .0 (2) 1 .10 f
f K f f
(1 f f

K).

f f f 201 f f () ..
* (“Company”, “Group”).

f

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

C K

2 201

A K M . G G K , M V , M . G , M V P M . K L ;
C H K M . H J , D . L , M . L M - A D M .

* F K

1 IMPORTANT NOTICE

1.1 f f f f

f f f f

1.2 f f f ff

1. f f f f f ff f ff

f (f f)

1. f f f f

2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDINGS OF THE COMPANY

2.1 f f

| | As at the end of the Reporting Period | As at the end of the previous year | Change recorded at the end of the Reporting Period compared with the end of the previous year (%) |
|----------|---|---|---|
| () | 0,0 2,2 , .2 | 2 , ,1 0, 1. | 1. |
| () () | 1 , 2 , ,1 .1 | 1 , 2,1 , .0 | 1. |
| | From the beginning of the year to the end of the Reporting Period (Jan - Mar) | From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Mar) | Year-on-year change (%) |
| (N) () | ,02 , 1 . | ,1 , 1. | - 0. |
| | From the beginning of the year to the end of the Reporting Period (Jan - Mar) | From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Mar) | Year-on-year change (%) |
| () | 2, , 2 , . | 2,0 , , 1.2 | 2 .2 |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

f

| Items | Current Amount (Jan - Mar) | Description |
|-------|-------------------------------|-------------|
| | 0, , 0. | |
| | 1,000.00 | |
| | 11, 0, 1 .21 | |
| | -1, ,0 2. | |
| | - , , 01. | |
| () | - , 02,0 1. | |
| | 110, , . | |

2.2 f f , f f 10 10

| The shareholding status of the Top 10 shareholders | | | | | |
|--|----------|------------------|-----------------------------|----------------------------------|------------------------------------|
| Name of the shareholder | Capacity | Shareholding (%) | Total number of shares held | Number of restricted shares held | Number of shares pledged or frozen |
| () , . | - - | 1.02 | 20, 1, 1 | 0 | |
| K | | 1 . | , 1 , 0 | 0 | |
| 10 f | | 1.22 | 2 , , 2 | 0 | |
| | | 0. | 1 ,2 1, | 0 | |
| | | 0. 0 | 1 ,000,000 | 0 | |
| 11 f | | 0. | 1 , ,22 | 0 | |
| | | 0. | 1 , 02, 0 | 0 | |
| | | 0. | 12, , 1 | 0 | |
| | | 0. 1 | 11, , | 0 | |
| | | 0. | 10,1 2, 0 | 0 | |
| 002 - -01 - | | | | | |

| The shareholding status of the Top 10 unrestricted shareholders of tradable shares | | |
|--|--|---------------------------|
| Name of the shareholder (in full) | Number of unrestricted tradable shares held at the end of the reporting period | Type and number of shares |
| () , . | 20, 1, 1 | |
| K (N) | , 1, 0 | f |
| 10 f | 2, , 2 | |
| — | 1,2 1, | |
| f — | 1,000,000 | |
| 11 f | 1, ,22 | |
| f | 1, 02, 0 | |
| f — | 12, , 1 | |
| f | 11, , | |
| f — 01 — 002 | 10,1 2, 0 | |
| f f | f f | f f |

N : K

f f

, . .

K

,

3 SIGNIFICANT EVENTS

.1 f f f f

✓

| Balance Sheet | | | | |
|------------------|---|---|-----------------|---------|
| Items | Closing balance as at the end of the Period | Opening balance as at the beginning of the Year | Ratio of change | Reasons |
| - | 2,0 , ,121.20 | 1, , 00, 2 . | % | - |
| - | 2 , 2 , 1. 2 | 12 , 1 ,1 1. 2 | 1 1% | - |
| Income Statement | | | | |
| Items | Current Amount | Amount of the last period | Ratio of change | Reasons |
| | (Jan - Mar 2014) | (Jan - Mar 2013) | | |
| | 1, ,0 , . | 1,1 2, , 0 . | % | f f |
| | 1, 2 ,2 . 2 | 2 ,0 ,110.1 | % | f & |
| f f (“-”) | 1, ,0 1. | 2, 1, 2. | - % | f f f |
| (“-”) | 01, 1 , . 2 | 2 ,200,01 .1 | % | f f f |
| - | , , 0 .0 | 1 ,0 0, . | - % | f f |
| | 2,11 , . | 0, 0 , . 0 | % | f f f |
| | - ,10 , 2. | 2 , , . | - 2% | f f f |

() 2 f²⁰¹ ,

, * (上

() f

Balance Sheet of the Company

31 M K 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

f

| Items | Closing balance as at the end of the Period | Opening balance as at the beginning of the Year |
|----------------------------|---|---|
| Current Assets: | | |
| | 1,010,000.00 | 2,110,000.00 |
| | | |
| | | |
| | | |
| | 121,000.00 | 200,000.00 |
| | 1,022,000.00 | 1,022,000.00 |
| | 1,002,000.00 | 1,002,000.00 |
| | 1,000,000.00 | 1,000,000.00 |
| | ,000,000.00 | 2,000,000.00 |
| | ,000,000.00 | ,000,000.00 |
| Non-current assets: | | |
| | | |
| | | |
| | | |
| | ,200,000.00 | ,000,000.00 |
| | | |
| | 1,022,000.00 | 201,000.00 |
| | | |
| | | |
| | | |
| | | |
| | 2,011,000.00 | ,000,000.00 |
| | | |
| | | |
| | | |
| | ,100,000.00 | ,022,000.00 |
| | ,000,000.00 | ,000,000.00 |
| | 1,102,000.00 | 12,000,000.00 |

Balance Sheet of the Company (Continued)

31 M K 2014

| Items | Closing balance as at the end of the Period | Opening balance as at the beginning of the Year |
|--|---|---|
| Current liabilities: | | |
| - | 10,000,000.00 | 0,000,000.00 |
| f | | |
| | | |
| | | |
| | , 0, . | 0, 2 , 11. |
| | 1 ,1 ,0 .02 | 22,22 , . |
| | 10 ,2 2, 0. | 1 , , 1 . |
| | | |
| | ,1 , . | , 12, 2 . |
| | 0,000,000.00 | 0,000,000.00 |
| | | |
| | 1,0 , 1 ,1 . 2 | 2 ,02 ,0 1.0 |
| Non-current liabilities: | | |
| - | 2 ,000,000.00 | 12 ,000,000.00 |
| | ,0 , 2 , 1. | ,0 , 1,2 0. |
| - | | |
| f | | |
| | | |
| f | | |
| | 1, ,000.00 | 2,0 0,000.00 |
| | , 02, 02, 1. | ,200, 1,2 0. |
| | , , 1 , . | , 2 , ,2 1. |
| Equity attributable to the owners (or equity attributable to shareholders): | | |
| - () | 2,2 , , .00 | 2,2 0, 2, .00 |
| | , ,20 ,2 . | , , 1,2 . 1 |
| | | |
| f | | |
| | , 0,1 . | , 0,1 . |
| | | |
| f | 1,0 , 22, 11. | 1,0 , 1,0 1. 2 |
| () | , , 1 , 1.0 | , 1, , .0 |
| () | 1 ,1 ,2 ,0 . | 12, , 2,1 . 0 |

f

f

ff

f

f

Consolidated Income Statement

J – M K 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

f

| Items | Current Amount | Amount of the Last Period |
|----------|----------------|---------------------------|
| | 2, , 2, . | 2,0 , , 1.2 |
| | 2, , 2, . | 2,0 , , 1.2 |
| | | |
| | | |
| | 2, 20, , 0 . 1 | 1, 2 , , 1 . |
| | 1, , 0 , . | 1,1 2, , 0 . |
| | | |
| f | | |
| | | |
| | | |
| | 1 , , 2.2 | 1 , 02, 2.1 |
| | 02, 1,211.12 | 0 , 02, . |
| | 1, 2 ,2 . 2 | 2 ,0 ,110.1 |
| | 2, 1, . | , ,210. |
| f | 1,220, 12. 0 | 1 , 2. 2 |
| f (“-”) | 1, , 0 1. | 2, 1, 2. |
| f (“-”) | 01, 1 , . 2 | 2 ,200,01 . 1 |
| | 2 , , 0, 2.1 | 1 , , . 1 |
| f (“-”) | | |
| f (“-”) | 0, , 0 2. | , 01,1 . |
| | , , 0 . 0 | 1 ,0 0, . |
| | , 12, . 0 | 2 ,0 . |
| f | , 1. | , 0,0 |
| f (“-”) | ,000,2 . | 2, 0 , 2 . |
| | 2,11 , . | 0, 0 , . 0 |
| f (“-”) | 2, 0, . | 12, , . |
| f | 1 , 1 , . 12 | 2,00 ,2 . 1 |
| f | , 0, . 1 | 0, 0, 1. |
| | | |
| (1) | 0.1 | 0.1 |
| (2) | 0.1 | 0.1 |
| | - ,10 , 2. | 2 , , . |
| | 1 , 0, 2. | , , 1.20 |
| f | 1, 1 ,1 . | 0, ,0 . 2 |
| | , 2 , . 2 | , 0 , 0 . |

f

f

ff

f

f

Income Statement of the Company

J – M K 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

f

| Items | Current Amount | Amount of the Last Period |
|------------|----------------|---------------------------|
| | | |
| | | |
| | | |
| | 2, 10, 1 . | 20, 2 ,00 .02 |
| | - ,1 ,20 . 1 | ,20 , . 2 |
| | | |
| f f (“-”) | | |
| (“-”) | 2 ,10 ,22 . | 2 , 1, . |
| f | 2 , 0 , 2 . | , ,2 2. |
| f (“-”) | -1,02 , . | 2 , 0, . |
| - | ,000.00 | ,0 2. |
| - | 2 0,000.00 | ,11 . 2 |
| f | | |
| f (“-”) | -1,20 , . | 2 , ,2 .02 |
| f (“-”) | -1,20 , . | 2 , ,2 .02 |
| | | |
| (1) | -0.00 | 0.12 |
| (2) | -0.00 | 0.12 |
| | | ,2 . 0 |
| | -1,20 , . | 2 , 0 , 1 . 2 |

f

f

ff

f

f

Consolidated Statements of Cash Flows

J - M K 2014

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

f

| Items | Current Amount | Amount of the Last Period |
|---|-----------------|---------------------------|
| I. Cash flow generated from operating activities: | | |
| f | ,0 , 22, . | 2, , , 0 . |
| f | | |
| f f | | |
| f f f | | |
| f | | |
| f | | |
| f f f f | | |
| f f | | |
| f | | |
| f f | 1 , 0 , . 0 | , 2 , . |
| f f f | 0, , 2 . | , , 0. |
| f | , 12 , , . 1 | 2, , , . |
| f | 1, 11, 1 , . | 1, 0 , , 2 2. |
| f | | |
| f | | |
| f f | | |
| f | | |
| f | | |
| f | | |
| f | | |
| f f f | , 20, 2 . 0 | 1 , , 22. |
| f | 2 , , 01. | 2 , 2 , 22 . |
| f | , , 1 . | , , 1. 0 |
| f f f | , 11 , , . | 2, 01, 1 , . 2 |
| f | , 02 , 1 . | , 1 , 1. |
| II. Cash flow generated from investing activities: | | |
| f | 1 , 1, 10 . | 1 , , 0. 10 |
| f | 0, 0 . | , 1 , . 00 |
| f f f | | |
| f | , 1, . | 2, 0 , 22. 22 |
| f | , 1 , . | |
| f | 0, 10 , 000. 00 | , 0, 000. 00 |
| f f f | 2 , , 1 1. | 1 , 2 , . 2 |
| f f f | , , . | 22 , 1, 2 . 21 |
| f | , , 2. | 1, 2 0, 000. 00 |
| f | | |
| f | | |
| f f | 1 , 10, . 0 | 1, 1 , 2. |
| f f f | 1, 2 1, 1 . 2 | 1 , , . |
| f | , 1 , . 1 | 2 , , 21. |
| f | - , 1 , 2 . | - , , 0 . |

Consolidated Statements of Cash Flows (Continued)

J – M K 2014

| Items | Current Amount | Amount of the Last Period |
|---|----------------|---------------------------|
| III. Cash flow generated from financing activities: | | |
| <i>f</i> | ,1 0.00 | |
| <i>f f</i> | ,1 0.00 | |
| <i>f</i> | 1, 2 , 1. | 1 ,0 , 02.00 |
| <i>f</i> | | |
| <i>f</i> | 21 , . | |
| <i>f f f f</i> | 2,20 , 20. | 1 ,0 , 02.00 |
| <i>f</i> | 12 ,2 ,2 . | 1 , 0, 1 . |
| <i>f f f</i> | 20 ,22 , . | 1 ,2 , 00. |
| <i>f</i> | 0,000,000.00 | 1, 2, 0 . |
| <i>f</i> | 1, , 1. | ,2 ,0 . 2 |
| <i>f f f f</i> | 0, , 0 .10 | 2, ,2 . |
| <i>f f f</i> | 1, , 1 . | -1 , 0 , . |
| IV. Effects of exchange rate fluctuations on cash and cash equivalents | , , .00 | - , 0 , . |
| V. Net increase of cash and cash equivalents | ,000,201. | - , 2,1 .2 |
| <i>f</i> | 2, 1 ,2 0, .2 | ,1 1, , 2.12 |
| VI. Closing balance of cash and cash equivalents | 2, ,2 0, 1.0 | , 1 , 2, 0 . |

f

f

ff

f

f

Statements of Cash Flows of the Company (Continued)

J – M K 2014

| Items | Current Amount | Amount of the Last Period |
|---|----------------|---------------------------|
| III. Cash flow generated from financing activities: | | |
| <i>f</i> | | |
| <i>f</i> | 0,000,000.00 | |
| <i>f</i> | | |
| <i>f</i> | 1, , , . 1 | , , 1. 0 |
| <i>f f f f</i> | 2, 2, , , . 1 | , , 1. 0 |
| <i>f</i> | | |
| <i>f f f</i> | 10 ,1 , . | 10 , 00,000.00 |
| <i>f</i> | 1, ,2 , . | 02, ,0 . 2 |
| <i>f f f f</i> | 1, , 2, 1. | 0 ,1 ,0 . 2 |
| <i>f f f</i> | , 1, 1. | -2 ,211, 0 .22 |
| IV. Effects of exchange rate fluctuations on cash and cash equivalents | ,12 , . 1 | - , 2, . 1 |
| V. Net increase of cash and cash equivalents | -1 ,11 , 2.11 | - 2,1 , 2. |
| <i>f</i> | 1 ,2 2, . 1 | 2,0 0, 1,0 . |
| VI. Closing balance of cash and cash equivalents | 0 ,1 , 0 . 0 | 1, , 1, 0. |

f

f

ff

f

f

* *F K*